Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

measurement of the speed and amplitude of an applied electrical impulse or nerve conduction velocity (NCV) in both sensory and motor nerves is a method of assessing the integrity or health of the nerve. A broader approach to quantification of clinical benefit involves the use of one of the many available composite scoring systems. These include the Total Neuropathy Score (TNS) and the narrower Neuropathy Impairment Score in the Lower Limbs (NIS-LL). The NIS-LL is a validated instrument that can be used to measure a clinically meaningful change in the neurological status of patients with DN over time. NIS-LL includes measures of motor and sensory nerve heath as well as reflex testing and is a quantifiable score of neurologic exam. These three measurements have all been used as primary or secondary endpoints of clinical benefit in Phase 3 studies.

"We are very encouraged by the safety of SB-509 and the improvements that we have seen in subjects with mild to moderate DN up to six-months after administration of a single dose of SB-509," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Particularly interesting are the encouraging and correlative gains observed in the NIS-LL and QST measurements of treated subjects which are independent and confirmatory. Both NIS-LL and QST have been used as end-points in previous pivotal large scale trials of other non-analgesic approaches for diabetic neuropathy. "

From a safety perspective, the Phase 1b data were consistent with previous observations that a single treatment of SB-509 was well tolerated and that no drug-related severe adverse events were observed. Injection site reactions were the most common adverse events reported and were mild and reversible. Importantly, subjects in the study were treated within the pharmacologically effective dose range that was demonstrated to be efficacious in preclinical animal studies.

"Although the primary end-point of
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Concepts (SMEV.PK), the manufacturer and developer of medical, ... that the Company has signed a co-branding preferred vendor ... franchise offering Health Clubs and Weight Loss Centers for ... as Mexico and Canada, SE Concepts expects a long ...
... May 25, 2011 Each month, millions of women suffer ... of the all-new AZO PMS™ -- the only ... women can now get relief from PMS with a fast ... PMS refers to a wide range of physical ...
Cached Medicine Technology:SpaCapsule Manufacturer Enters Preferred Vendor Agreement With Prominent Women's Fitness Franchise 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 2New AZO PMS™ Delivers Fast, Natural Relief from Symptoms Associated with Premenstrual Syndrome 3
(Date:7/11/2014)... 11, 2014 The International Concussion ... at the Best Buy Theater in Times Square, ... to the growing concussion epidemic that is plaguing ... levels of competition. , The Symposium gathers more ... researchers, coaches, professional athletes and legal scholars for ...
(Date:7/11/2014)... Newport Beach, CA (PRWEB) July 11, 2014 ... product pure Artichoke Leaf Extract dietary supplements to aid ... flow, an action necessary to facilitate metabolism of fat. ... facilities, Superior Labs Artichoke Leaf Extract is available in ... of pure artichoke extract. , Health Benefits of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... begin this August in New York. ... cover: , -Myofascial Trigger Point Therapy, ... -Mobilization & Thrust Manipulation, -Neuroobilization & Neurodynamics, ... prescribing to a single, isolated manual therapy ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 This morning(July 9th, ... 13--Good Morning Memphis to discuss the illegal immigration crisis at ... town of McAllen, Texas. , Dr. Flinn told Good Morning ... is absolutely wide open… The problem is that they do ... Thousands of people per day are coming into the border; ...
Breaking Medicine News(10 mins):Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 3Health News:Hands-On Seminars, the Leader in Manual Therapy Continuing Education, Announces Series of Comprehensive Hands-On Training Courses 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2
... developed deposits, study finds , , WEDNESDAY, Feb. 4 (HealthDay ... sickened more than 50,000 kids last fall resulted in ... developing kidney problems, according to just-released Beijing research on ... in Taiwan and 10 percent of those who drank ...
... (AUA) will hold its Annual Scientific Meeting in Chicago, ... Meeting is the largest meeting of urologic professionals in ... urologists and healthcare professionals from around the world. This ... more than 300 exhibitors will showcase their products and ...
... Pharmacies will host an in-store Healthy Heart Event., ... well as provide information to help patients better ... Pharmacists will also help patients, ... blood pressure and heart disease., WHY: ...
... /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: ... will be presenting at the National Cancer Institute,s Office ... series. The title of the presentation is "Selective Cytotoxic ... Effects in Patients with Advanced Breast Cancer," and will ...
... provider of complete solutions for the analysis of Next ... Molecular Biology Laboratory (EMBL) installed a Genomatix Mining Station ... Facility. These systems deliver the only complete and integrated ... generated by the sequencer, to a molecular level understanding ...
... is seeking nominations for the Fourth Annual Bioscience Awards ... interested in nominating a company or individual for an ... are: Entrepreneurial, Best New Product or Progress, Leadership in ... submit documentation and narratives that fulfill several criteria and ...
Cached Medicine News:Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 3Health News:Bionovo Announces Presentation at the National Cancer Institute 2Health News:Bionovo Announces Presentation at the National Cancer Institute 3Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 2Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 3Health News:GBC Seeks Nominations for Fourth Annual Bioscience Awards 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: